FDA approves Lilly's Jaypirca for previously untreated CLL and SLL
- The FDA approved Jaypirca (pirtobrutinib) for previously untreated chronic lymphocytic leukemia and small lymphocytic lymphoma.
- It moves the non-covalent BTK inhibitor from later-line use into the first-line setting.
💡 Points
First-line is where the BTK market's volume sits, so this is the label that matters commercially. It puts a non-covalent inhibitor directly against the covalent incumbents, where it competes on tolerability and on not depending on the Cys481 bond. Watch how payers and guidelines place it relative to fixed-duration venetoclax regimens.